{"meta":{"query_hash":"6ac19511148b","filters":{"venue":"Section 4: Clinical pharmacy services"},"cohort_total":13,"direct_labels_cover":0,"predictions_cover":13,"exported":13,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6ac19511148b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Section+4%3A+Clinical+pharmacy+services"},"results":[{"id":"W2921353678","doi":"10.1136/ejhpharm-2019-eahpconf.269","title":"4CPS-120 Erlotinib in non-small-cell lung cancer without epidermal growth factor receptor activating mutations","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Epidermal growth factor receptor; Oncology; Lung cancer; Chemotherapy; Taxane; Erlotinib Hydrochloride; Adverse effect; Cancer; Breast cancer","score_opus":0.038105665510673306,"score_gpt":0.4265117572884367,"score_spread":0.3884060917777634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921353678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895211,0.00028071512,0.000058203415,0.002047624,0.0026699377,0.0016140594,0.00006625272,0.00014377665,0.0035983347],"genre_scores_gemma":[0.9931111,0.00037396137,0.00078576023,0.0023668648,0.0010649477,0.00022341598,0.00015840757,0.00005948894,0.0018560826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976998,0.00014731692,0.0008718575,0.00061559916,0.00027407813,0.00039136427],"domain_scores_gemma":[0.99844116,0.00039895883,0.0003895369,0.0002448043,0.00026077352,0.0002647936],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002788546,0.0002792147,0.00051382417,0.00017732942,0.00014656325,0.000050912065,0.00013862106,0.0001314009,0.001843556],"category_scores_gemma":[0.00004717434,0.00024355641,0.000202727,0.00047523197,0.00003618236,0.00045555114,0.000052934327,0.0006335304,0.00015833146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033608318,0.0006065827,0.9859198,0.0006930245,0.0002709917,0.0000059529416,0.0016713,0.00020873538,0.0052274275,0.0000048302622,0.00025629904,0.0047990223],"study_design_scores_gemma":[0.021121748,0.00037915973,0.9316035,0.00083395594,0.00064498815,0.000011342507,0.0016994323,0.017291816,0.010740623,0.000033959477,0.015040328,0.00059913576],"about_ca_topic_score_codex":0.0041204467,"about_ca_topic_score_gemma":0.00068292697,"teacher_disagreement_score":0.054316238,"about_ca_system_score_codex":0.0002675132,"about_ca_system_score_gemma":0.00034859497,"threshold_uncertainty_score":0.9990689},"labels":[],"label_agreement":null},{"id":"W2944589946","doi":"10.1136/ejhpharm-2019-eahpconf.403","title":"4CPS-254 Biosimilar rituximab – a year beyond","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Kidney Foundation of Canada","keywords":"Biosimilar; Rituximab; Medicine; Discontinuation; Rheumatoid arthritis; Pharmacy; Retrospective cohort study; Internal medicine; Oncology; Lymphoma; Family medicine","score_opus":0.034963637577777165,"score_gpt":0.3810492240157845,"score_spread":0.34608558643800735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944589946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95383155,0.0023425687,0.00007077746,0.006162045,0.01508047,0.0006314881,0.000097552256,0.00037564445,0.021407917],"genre_scores_gemma":[0.9788494,0.00062476925,0.00079049886,0.012052721,0.00065611047,0.000011576367,0.00006177589,0.000036313446,0.0069168364],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750286,0.0005559264,0.00074861327,0.0006549348,0.00008267353,0.00045500023],"domain_scores_gemma":[0.99869657,0.00044159658,0.0002232749,0.00041575907,0.00012986302,0.00009291705],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011462474,0.00026056802,0.00054600375,0.000101427984,0.00015049189,0.000043212523,0.00039920406,0.00041233632,0.011528249],"category_scores_gemma":[0.00005099558,0.00021028204,0.00035209296,0.00031093962,0.00018060644,0.00020669182,0.00017374785,0.00087031943,0.0048630564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049050674,0.0053722397,0.51179725,0.00090528,0.0028740128,0.00002995037,0.00044052882,0.000011701624,0.30265576,0.002126279,0.082738124,0.086143814],"study_design_scores_gemma":[0.00615474,0.00034600735,0.012551292,0.000041843094,0.00018428166,0.000021011234,0.00017435462,0.00015581379,0.022209525,0.0007888894,0.9569972,0.0003750001],"about_ca_topic_score_codex":0.000104091465,"about_ca_topic_score_gemma":0.000033398424,"teacher_disagreement_score":0.8742591,"about_ca_system_score_codex":0.00002523202,"about_ca_system_score_gemma":0.00004630303,"threshold_uncertainty_score":0.9959118},"labels":[],"label_agreement":null},{"id":"W2945528492","doi":"10.1136/ejhpharm-2019-eahpconf.404","title":"4CPS-255 The effect of an enhancing medication adherence programme for a type 2 diabetes mellitus network","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chulabhorn Research Institute; Copperbelt University; Kidney Foundation of Canada","keywords":"Medicine; Pharmacist; Pharmacy; Test (biology); Family medicine; Type 2 Diabetes Mellitus; Diabetes mellitus","score_opus":0.07543680084374962,"score_gpt":0.4363149610199399,"score_spread":0.36087816017619023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945528492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992766,0.0010063568,0.00016689421,0.0010900267,0.0026708026,0.0017890764,0.0000024701415,0.00009801414,0.00041036334],"genre_scores_gemma":[0.9949805,0.00030985856,0.0005029169,0.0020391229,0.0015124646,0.00020826202,0.00008687472,0.00001913404,0.0003408617],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797213,0.00028440313,0.0007186617,0.0003839869,0.0003339272,0.00030689966],"domain_scores_gemma":[0.9977057,0.00090316904,0.00047015076,0.00045509,0.00026160342,0.00020430125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023620292,0.00015642401,0.00041600908,0.000031427804,0.000097302116,0.00002113646,0.00027585894,0.00009770059,0.00070287986],"category_scores_gemma":[0.00021711807,0.00010099555,0.00014590565,0.00036690827,0.00008800684,0.00017482914,0.00003369981,0.00031941695,0.00026466078],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031382896,0.00049180357,0.6077268,0.0037209752,0.000439551,0.0000010695194,0.00035927063,0.000116450276,0.013916464,0.00009611628,0.003005158,0.36698806],"study_design_scores_gemma":[0.02248877,0.023886818,0.18326344,0.0030619733,0.0017520335,0.000021371005,0.0009476162,0.1642094,0.07258232,0.0016196095,0.5252533,0.00091335824],"about_ca_topic_score_codex":0.00007439697,"about_ca_topic_score_gemma":0.000033034496,"teacher_disagreement_score":0.52224815,"about_ca_system_score_codex":0.000020377533,"about_ca_system_score_gemma":0.00011439229,"threshold_uncertainty_score":0.76960415},"labels":[],"label_agreement":null},{"id":"W3016600733","doi":"10.1136/ejhpharm-2020-eahpconf.281","title":"4CPS-180 From evidence based medicine to practice: gum chewing for postoperative recovery of gastrointestinal function after colorectal surgery with interprofessional teamwork","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Enhanced Recovery After Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; University Hospital Southampton NHS Foundation Trust","keywords":"Medicine; Randomized controlled trial; Colorectal surgery; Teamwork; Defecation; Colostomy; Physical therapy; Surgery; Abdominal surgery","score_opus":0.0752212007927984,"score_gpt":0.3995477239843968,"score_spread":0.3243265231915984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016600733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9422399,0.0003240939,0.025065204,0.027873525,0.0032207798,0.0010238601,0.000058682515,0.0001342154,0.000059731196],"genre_scores_gemma":[0.94708276,0.000053966898,0.011071084,0.038496934,0.0028480922,0.00020325964,0.0001241537,0.000055004508,0.00006472494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99644524,0.00049469393,0.0013172148,0.0008288324,0.0005760255,0.00033801838],"domain_scores_gemma":[0.98696244,0.010669203,0.00067481276,0.00024418184,0.0009612868,0.0004880713],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014972446,0.00034284996,0.0009428312,0.00017017289,0.000103598504,0.000027821681,0.00013657408,0.000105974665,0.0007622387],"category_scores_gemma":[0.0038152635,0.0002607619,0.00030596773,0.0006272187,0.00012418555,0.0010354836,0.000085247986,0.0007201632,0.000030958156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3605815,0.00074569916,0.5520915,0.0011418543,0.0005773719,0.00011358705,0.000964969,0.00036945043,0.0617199,0.00000135601,0.0068599023,0.014832929],"study_design_scores_gemma":[0.014303954,0.024176758,0.8051064,0.0468734,0.0030639116,0.00024643613,0.00494598,0.017622119,0.04544895,0.00010483478,0.03654341,0.0015638502],"about_ca_topic_score_codex":0.00027731818,"about_ca_topic_score_gemma":0.00007595194,"teacher_disagreement_score":0.34627753,"about_ca_system_score_codex":0.00010464997,"about_ca_system_score_gemma":0.0005667442,"threshold_uncertainty_score":0.99998444},"labels":[],"label_agreement":null},{"id":"W3016926053","doi":"10.1136/ejhpharm-2020-eahpconf.280","title":"4CPS-179 The wide review of polypharmacy in the frail older person","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; University Hospital Southampton NHS Foundation Trust","keywords":"Polypharmacy; Computer science; Older people; Gerontology; Medicine; Intensive care medicine","score_opus":0.2952603473552379,"score_gpt":0.5051458419799638,"score_spread":0.20988549462472594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016926053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.515739,0.032741588,0.00002772746,0.43921146,0.0016502741,0.0022784884,0.000018374903,0.000100122365,0.008232952],"genre_scores_gemma":[0.70276153,0.02209048,0.000027650374,0.27418125,0.0008253575,0.000024606104,0.000016179689,0.000016719412,0.000056252044],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968495,0.00087421096,0.0010135212,0.00037484482,0.00060836255,0.0002795678],"domain_scores_gemma":[0.9966597,0.0021855927,0.00045827255,0.000322765,0.00013610227,0.0002375707],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019713107,0.00021806924,0.0005360712,0.000038536873,0.0001113034,0.000027409014,0.00045376978,0.00006144589,0.0017520002],"category_scores_gemma":[0.00060695485,0.00011718758,0.00038668557,0.00069232885,0.000119830416,0.00031926902,0.000075319105,0.0013105446,0.00012238594],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032575978,0.0017448401,0.8786527,0.02570666,0.00058837177,0.00008796011,0.005878482,0.00002167945,0.0007741845,0.00008392327,0.04878496,0.03441868],"study_design_scores_gemma":[0.0050641648,0.0003119827,0.08056637,0.0017582657,0.00083368865,0.00002983914,0.0012944803,0.005658835,0.00035645935,0.00002253782,0.9038954,0.0002079967],"about_ca_topic_score_codex":0.0002663054,"about_ca_topic_score_gemma":0.000016406471,"teacher_disagreement_score":0.8551104,"about_ca_system_score_codex":0.000020037685,"about_ca_system_score_gemma":0.00008553724,"threshold_uncertainty_score":0.9991605},"labels":[],"label_agreement":null},{"id":"W3016962124","doi":"10.1136/ejhpharm-2020-eahpconf.198","title":"4CPS-097 Secondline treatment of metastatic non-small cell lung cancer with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Lung cancer; Nivolumab; Atezolizumab; Chemotherapy; Performance status; Retrospective cohort study; Cancer; Adverse effect; Immunotherapy","score_opus":0.05666603131101178,"score_gpt":0.38195838794369497,"score_spread":0.3252923566326832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016962124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897315,0.004012099,0.00013562734,0.0037168465,0.00064886163,0.0012011653,0.00009726449,0.00008515687,0.0003715005],"genre_scores_gemma":[0.992585,0.0020861167,0.0018302238,0.0019395528,0.0009953633,0.00012007012,0.00013683081,0.000053872267,0.00025296793],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975357,0.00014634416,0.0011735632,0.00056366465,0.00028294546,0.00029779403],"domain_scores_gemma":[0.9983329,0.00018380229,0.000565421,0.00029430297,0.00019360817,0.00042996526],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002813006,0.0003575243,0.00092784123,0.00007140022,0.00007991667,0.000020512194,0.00010242408,0.0000587026,0.0010520598],"category_scores_gemma":[0.000010639422,0.00024125144,0.00044782623,0.00037424258,0.00007262454,0.00011983071,0.000042820553,0.00026383167,0.000026646645],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024029749,0.01971618,0.78009164,0.013856714,0.013679965,0.0009241948,0.009053528,0.0035255465,0.05762848,0.000012313715,0.0012427921,0.07623888],"study_design_scores_gemma":[0.12297442,0.026713166,0.1022988,0.001278016,0.01887833,0.00012720285,0.0038309374,0.056133907,0.54165083,0.000031508836,0.12452063,0.0015622603],"about_ca_topic_score_codex":0.0022884472,"about_ca_topic_score_gemma":0.0002898037,"teacher_disagreement_score":0.67779285,"about_ca_system_score_codex":0.00010445735,"about_ca_system_score_gemma":0.00024497596,"threshold_uncertainty_score":0.9998611},"labels":[],"label_agreement":null},{"id":"W3137967144","doi":"10.1136/ejhpharm-2021-eahpconf.232","title":"4CPS-400 The role and value of a ward based pharmacist in the intensive care unit: the critical care physicians’ and nurses’ perceptions","year":2021,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Likert scale; Pharmacist; Intensive care unit; Medicine; Scale (ratio); Nursing; Clinical pharmacy; Critical care nursing; Family medicine; Pharmacy; Psychology; Health care; Intensive care medicine","score_opus":0.1463255160144417,"score_gpt":0.5062585645855626,"score_spread":0.35993304857112096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137967144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650415,0.00445719,0.000013013372,0.027601875,0.0009508033,0.0005802148,0.000059338905,0.000026785692,0.0012692701],"genre_scores_gemma":[0.9643398,0.0008090467,0.00003308624,0.034222893,0.0004756048,0.00003516331,0.000046498808,0.000017152375,0.000020788177],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9974174,0.0010865354,0.00053235964,0.00036034518,0.00036253256,0.00024085295],"domain_scores_gemma":[0.9954169,0.0032026938,0.00013849615,0.00031754392,0.0008031737,0.00012123457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005230871,0.00019410593,0.00034219073,0.000042789805,0.00033428578,0.000071795184,0.00019080869,0.0000725205,0.00013420389],"category_scores_gemma":[0.0004393486,0.00010498171,0.00017900355,0.0003770579,0.0004944238,0.00020212369,0.000099593504,0.0010797497,0.000007963194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014051438,0.0005042608,0.92374116,0.0012403812,0.00018968486,0.000053646327,0.04289107,0.00008342234,0.0013707284,0.00024753207,0.00019001412,0.028082957],"study_design_scores_gemma":[0.0071369726,0.00041126396,0.35329694,0.00035336186,0.0019106633,0.0001289876,0.44803512,0.045017593,0.0014436562,0.0002606983,0.14171046,0.00029430122],"about_ca_topic_score_codex":0.00027013948,"about_ca_topic_score_gemma":0.00017741261,"teacher_disagreement_score":0.5704442,"about_ca_system_score_codex":0.000022247837,"about_ca_system_score_gemma":0.000104587074,"threshold_uncertainty_score":0.46910352},"labels":[],"label_agreement":null},{"id":"W3138660907","doi":"10.1136/ejhpharm-2021-eahpconf.178","title":"4CPS-346 Evaluation of the implementation of ‘inhaler interviews’ during medication reconciliation in the pneumology service","year":2021,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Société de Pneumologie de Langue Française","keywords":"Inhaler; Checklist; Medicine; Pharmacy; Medical emergency; Physical therapy; Emergency medicine; Asthma; Nursing; Psychology; Internal medicine","score_opus":0.12528372128493975,"score_gpt":0.4758899914348665,"score_spread":0.35060627014992674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138660907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896374,0.0002929969,0.000008743129,0.00749353,0.0013277452,0.000636603,0.0000071784934,0.000014142729,0.00058168924],"genre_scores_gemma":[0.9950498,0.0002209962,0.000019024304,0.004206244,0.0003531873,0.00004247856,0.000069280984,0.000009516028,0.000029521358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605596,0.0016602663,0.001222091,0.00025949153,0.0006808931,0.000121283716],"domain_scores_gemma":[0.99748725,0.00023032668,0.0007242103,0.0003500242,0.0011698313,0.000038345304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036497759,0.00010901689,0.00026310916,0.00010027449,0.000080503356,0.000008849953,0.00016744374,0.000097549644,0.0008369952],"category_scores_gemma":[0.00015093522,0.00007243005,0.00015853405,0.0006914893,0.000050955376,0.00018974778,0.000057070225,0.0003243566,0.000012182918],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004975569,0.0013762348,0.7762233,0.0024993895,0.00036554632,0.0000061022556,0.016096247,0.0008303928,0.12216012,0.0000902047,0.00040736274,0.079447515],"study_design_scores_gemma":[0.0054679597,0.00007658787,0.9212652,0.00021769188,0.0004141951,0.000040602434,0.008058582,0.00647956,0.055148568,0.00009277443,0.0026430697,0.00009521545],"about_ca_topic_score_codex":0.00034586823,"about_ca_topic_score_gemma":0.002399969,"teacher_disagreement_score":0.14504187,"about_ca_system_score_codex":0.00008805776,"about_ca_system_score_gemma":0.00037029517,"threshold_uncertainty_score":0.9164511},"labels":[],"label_agreement":null},{"id":"W4293230230","doi":"10.1136/ejhpharm-2022-eahp.129","title":"4CPS-099 Clinically relevant drug–drug interaction events in patients with abiraterone, enzalutamide or apalutamide treatment","year":2022,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Rio Tinto","keywords":"Enzalutamide; Medicine; Pharmacology; Prostate cancer; Drug interaction; Internal medicine; Drug; Cancer; Androgen receptor","score_opus":0.05257616929045679,"score_gpt":0.41697915321367546,"score_spread":0.3644029839232187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293230230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934112,0.00017117141,0.000002674199,0.0021364419,0.0019449792,0.0017865231,0.00006265352,0.00014350469,0.00034084707],"genre_scores_gemma":[0.99149895,0.0009424459,0.00011396148,0.0016835366,0.0005182568,0.00042248055,0.00043774748,0.0000674771,0.004315175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550915,0.0007806346,0.0014108814,0.0008878315,0.00086231926,0.0005491721],"domain_scores_gemma":[0.9979852,0.00053157884,0.0004710204,0.0004318683,0.00021690052,0.0003634481],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010981447,0.00037584445,0.0006951922,0.00029780634,0.0003250771,0.000032121767,0.00023372583,0.00006266462,0.0013189033],"category_scores_gemma":[0.000048956077,0.00025020947,0.00024117541,0.00064908015,0.00008042899,0.0003926481,0.00018983908,0.0010264548,0.00009356408],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050601706,0.005350169,0.9268472,0.00016692537,0.0004319397,0.000100102996,0.00084083865,0.00030789306,0.00007614766,8.6775447e-7,0.0003701684,0.014906041],"study_design_scores_gemma":[0.05568903,0.0074881357,0.8534317,0.00032517387,0.00044790213,0.000029589131,0.0014433262,0.0018410865,0.0005492133,0.00006431364,0.07819221,0.00049831835],"about_ca_topic_score_codex":0.0016452154,"about_ca_topic_score_gemma":0.0009855422,"teacher_disagreement_score":0.077822044,"about_ca_system_score_codex":0.0010610089,"about_ca_system_score_gemma":0.00040575743,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W4293230261","doi":"10.1136/ejhpharm-2022-eahp.128","title":"4CPS-097 Role of the pharmacist in the care of the lung transplant patient","year":2022,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Transplantation: Methods and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pharmacist; Lung transplantation; Bronchiectasis; Cystic fibrosis; Lung; Transplantation; Pulmonary function testing; Obstructive lung disease; Multidisciplinary team; Internal medicine; Physical therapy; Intensive care medicine; Pediatrics; COPD; Pharmacy; Family medicine; Nursing","score_opus":0.041331340812046626,"score_gpt":0.408605612208214,"score_spread":0.36727427139616736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293230261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993878,0.00119875,0.000009041719,0.0016049389,0.0017324246,0.00069508917,0.0001468531,0.000016281614,0.0007186121],"genre_scores_gemma":[0.9961135,0.00026133435,0.000053867087,0.0032977627,0.00016504877,0.00004635712,0.000020700068,0.000012096024,0.000029331086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973603,0.0010028108,0.00074850715,0.00020410566,0.0005381757,0.0001460974],"domain_scores_gemma":[0.99877334,0.00048890116,0.00030639005,0.00031376447,0.00007758141,0.000040018615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008122249,0.00012253945,0.0002758547,0.000043169024,0.00021640514,0.0000068515374,0.00040638918,0.000032475655,0.00020824725],"category_scores_gemma":[0.0000142956815,0.00006128438,0.00034495562,0.00045979285,0.000082043014,0.000056019613,0.000057793797,0.0006571315,8.6934796e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001023552,0.00038083334,0.966421,0.0005712005,0.00010165415,0.000005327334,0.019163972,0.00051695673,0.004640758,0.00005737444,0.000088248045,0.007029139],"study_design_scores_gemma":[0.0057184477,0.00022947624,0.9111556,0.00017623615,0.0007461145,0.000072345814,0.0146378325,0.0027790277,0.018812938,0.00010703086,0.045413494,0.00015149082],"about_ca_topic_score_codex":0.0005856474,"about_ca_topic_score_gemma":0.00018732816,"teacher_disagreement_score":0.055265415,"about_ca_system_score_codex":0.00003410988,"about_ca_system_score_gemma":0.00008534811,"threshold_uncertainty_score":0.2854946},"labels":[],"label_agreement":null},{"id":"W4360614867","doi":"10.1136/ejhpharm-2023-eahp.52","title":"4CPS-003 Experiences with a best possible medication history (BPMH) conducted by pharmacy students in the hospital setting: a scoping review","year":2023,"lang":"en","type":"review","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Patient safety; Medicine; Health care; Hospital pharmacy; MEDLINE; Clinical pharmacy; Family medicine; Medical education; Medical emergency","score_opus":0.37382453718878483,"score_gpt":0.5799558731640854,"score_spread":0.20613133597530053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360614867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041505364,0.9817858,0.000002236383,0.0028796827,0.0035605002,0.0069531086,0.00002936464,0.0002137434,0.00042506438],"genre_scores_gemma":[0.0006129916,0.98365444,0.000025874446,0.011983937,0.0010266931,0.0015874141,0.0005936899,0.000107486034,0.00040746236],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99176747,0.0019216385,0.0028521102,0.001188491,0.0016456845,0.0006246094],"domain_scores_gemma":[0.994136,0.0024194596,0.002149948,0.0006446822,0.00019436452,0.00045555728],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0038141804,0.0007551414,0.0024828133,0.00024994885,0.00020939772,0.00010997636,0.0010927897,0.0002233755,0.00088778476],"category_scores_gemma":[0.00050070335,0.00046525078,0.00060416124,0.0012310909,0.00029522553,0.000737004,0.00021117573,0.0025103963,0.0002886682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073419715,0.0069491146,0.016424717,0.6530014,0.0023874796,0.000431604,0.0072089555,6.323439e-7,0.0000024471415,0.0000035309429,0.043658234,0.26919767],"study_design_scores_gemma":[0.0028399394,0.00037419508,0.000044536202,0.17545131,0.0037678953,0.00007666762,0.0014527865,0.00006896379,9.331962e-7,0.0000012303316,0.8154475,0.00047404988],"about_ca_topic_score_codex":0.0005044362,"about_ca_topic_score_gemma":0.00007347848,"teacher_disagreement_score":0.77178925,"about_ca_system_score_codex":0.00035832525,"about_ca_system_score_gemma":0.0010636358,"threshold_uncertainty_score":0.99979085},"labels":[],"label_agreement":null},{"id":"W4393005622","doi":"10.1136/ejhpharm-2024-eahp.183","title":"4CPS-079 Indirect comparison of il-13 inhibitors plus topical corticosteroids in moderate to severe atopic dermatitis","year":2024,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Dupilumab; Placebo; Corticosteroid; Internal medicine; Clinical endpoint; Gastroenterology; Randomized controlled trial; Dermatology","score_opus":0.05583459261996076,"score_gpt":0.4134032319752196,"score_spread":0.35756863935525884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393005622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905388,0.0015433624,0.000048008696,0.0033088666,0.0026732509,0.0004367956,0.000022828122,0.00015926603,0.0012688653],"genre_scores_gemma":[0.9952396,0.00015700523,0.000075846576,0.0036929955,0.00051505724,0.00003309639,0.00004311485,0.000020524893,0.00022272115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99771804,0.00022821686,0.0011242963,0.0004099816,0.00026122306,0.00025824606],"domain_scores_gemma":[0.99895406,0.00036375504,0.00011143694,0.00021027724,0.00008775188,0.00027272303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022997553,0.00019002565,0.00068429,0.0002150118,0.000057149387,0.000042135453,0.00012733274,0.00016705826,0.00035250586],"category_scores_gemma":[0.000075128,0.00017125536,0.00019129683,0.00042853126,0.00007233765,0.00022946791,0.000089146655,0.00057503174,0.00012807333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061007746,0.00050651556,0.9714418,0.001553247,0.00018704169,0.00019083136,0.0013669066,0.00032101877,0.00017721845,0.00001738572,0.007140511,0.016487451],"study_design_scores_gemma":[0.004626037,0.0003032766,0.8835452,0.0011877805,0.000331727,0.0001691445,0.00050510705,0.0468471,0.006158151,0.00035301948,0.05562275,0.00035066486],"about_ca_topic_score_codex":0.00021199546,"about_ca_topic_score_gemma":0.0004937087,"teacher_disagreement_score":0.087896556,"about_ca_system_score_codex":0.000054024953,"about_ca_system_score_gemma":0.00015102343,"threshold_uncertainty_score":0.69835913},"labels":[],"label_agreement":null},{"id":"W4393026380","doi":"10.1136/ejhpharm-2024-eahp.245","title":"4CPS-141 Real-life impact of including montelukast as premedication on the incidence of infusion-related reactions to isatuximab and description of risk factors","year":2024,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Leslie Dan Faculty of Pharmacy, University of Toronto; University of Waterloo","keywords":"Discontinuation; Tolerability; Medicine; Regimen; Placebo; Premedication; Odds ratio; Adverse effect; Number needed to treat; Internal medicine; Confidence interval; Relative risk; Anesthesia","score_opus":0.1080169857880549,"score_gpt":0.44373312146846533,"score_spread":0.3357161356804104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393026380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955447,0.00011202859,0.000048199476,0.0008224437,0.0010322733,0.0006210504,0.000055417117,0.00010827551,0.0016556589],"genre_scores_gemma":[0.9977956,0.0017169906,0.00004621503,0.00010282242,0.00019751767,0.000015901413,0.000033144075,0.000027247406,0.00006459348],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974421,0.00027613438,0.0012486045,0.00037727546,0.00048785305,0.00016798956],"domain_scores_gemma":[0.99652326,0.001807278,0.00068196806,0.00036259418,0.00036218486,0.0002627408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001294575,0.00019939455,0.00044281557,0.00040713165,0.0001388628,0.000019201616,0.00013080252,0.00015189203,0.000086738175],"category_scores_gemma":[0.0015988827,0.00013738882,0.0002819662,0.0010129017,0.00014021748,0.0004096697,0.00009255762,0.0007584765,0.000020335607],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012202358,0.0020311114,0.44673908,0.0015266848,0.0021999811,0.00000767636,0.015286576,0.002424326,0.49087173,0.0006180104,0.0004069241,0.036667667],"study_design_scores_gemma":[0.001217031,0.0004477126,0.97040874,0.001510419,0.00067463535,0.000022652053,0.0028477593,0.010889697,0.010055774,0.00037889194,0.001389187,0.00015747345],"about_ca_topic_score_codex":0.018480282,"about_ca_topic_score_gemma":0.00022910933,"teacher_disagreement_score":0.5236697,"about_ca_system_score_codex":0.0001743628,"about_ca_system_score_gemma":0.0003007832,"threshold_uncertainty_score":0.98805577},"labels":[],"label_agreement":null}]}